thebench.bio #1 Ecosystem for the Bio-Tech Industry

Life Sciences Daily Summary

Life Sciences Daily Summary: What Happened on November 16, 2026

FDA rejects Summit’s ivonescimab application and approves AstraZeneca’s bladder cancer regimen

Amylyx reported Phase 3 avexitide results, Seawolf raised $100 million and disclosed a Sanofi deal, and Sofinnova closed a €725 million fund.

  • Updated
  • Read from 8 articles, 5 publications

Today in brief

The FDA turned down Summit’s ivonescimab application for advanced lung cancer because the trial did not establish a survival benefit.1 AstraZeneca won FDA approval for an Imfinzi combination for some adults with muscle-invasive bladder cancer who cannot or will not receive cisplatin chemotherapy.2 Amylyx said avexitide reduced hypoglycemic events by 55% versus placebo in a Phase 3 trial.3

Seawolf raised $100 million to develop nonviral gene delivery and disclosed a Sanofi partnership worth up to $1.2 billion.45 Sofinnova Partners closed a €725 million fund focused mainly on later-stage European life-sciences companies.67

FDA rejects ivonescimab after survival benefit fell short

The FDA declined Summit Therapeutics’ application for ivonescimab with platinum-based chemotherapy in certain patients whose lung cancer progressed after EGFR-targeted treatment.1 The agency said the Phase 3 HARMONi trial’s progression-free survival result did not establish a favorable benefit-risk profile without a statistically significant overall survival gain.1

The trial’s primary overall survival analysis showed a positive trend, but it was not statistically significant.1 Ivonescimab remains unapproved in Summit’s licensed territories, including the United States and Europe. China authorized it in May 2024 for certain patients.1

FDA approves Imfinzi combination before and after bladder surgery

The FDA approved AstraZeneca’s Imfinzi with enfortumab vedotin for adults with muscle-invasive bladder cancer who cannot or will not receive cisplatin-based chemotherapy.2 Patients receive both drugs before bladder-removal surgery, then Imfinzi alone afterward.2

In the Phase 3 VOLGA study, the regimen cut the risk of progression, recurrence, surgery not taking place, or death by 49% versus the comparison group.2 Estimated two-year event-free survival was 64% with the combination and 45% with the comparison treatment.2 Grade 3 or 4 adverse events from any cause affected 64% of combination recipients and 44% of comparison participants.2

Avexitide reduced low-blood-sugar events in Phase 3

Amylyx said once-daily avexitide lowered the combined rate of confirmed moderate and severe hypoglycemic events by 55% versus placebo during LUCIDITY’s 16-week blinded phase.3 The trial enrolled 78 adults whose condition developed after Roux-en-Y gastric bypass surgery.3

The average event rate was 0.55 per week with avexitide and 1.24 with placebo, a statistically significant difference.3 Reported side effects were mainly mild to moderate gastrointestinal or injection-site events. No treatment-related serious adverse events or deaths occurred.3

Seawolf raises $100 million and signs Sanofi gene-delivery deal

Seawolf Therapeutics raised $100 million from investors including Versant Ventures, Eli Lilly, MPM BioImpact, and Novartis’ venture arm.45 The startup is developing ways to deliver genetic medicines without viruses. Viral vectors can prompt antibodies that block repeat dosing, while high doses may cause serious side effects.4

Seawolf also disclosed a Sanofi partnership valued at up to $1.2 billion.5

Sofinnova closes €725 million fund for later-stage companies

Sofinnova Partners closed Crossover II at €725 million, targeting about 15 biopharma and medical-device companies, mainly in Europe.68 At €725 million, the fund is 63% larger than its predecessor. It will back companies advancing through clinical development toward commercialization.6

Sofinnova closes €725 million fund for later-stage companies

It has already invested in Hemab Therapeutics, CellCentric, and Neurent Medical.6 Sofinnova said companies backed by its first crossover fund later raised a combined €3.4 billion.6